Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
Completed
Novartis
Phase 2/Phase 3
2006-10-01
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol
when delivered via an SDDPI in patients with COPD. All patients will receive 1 day of
treatment with each of the following: indacaterol 150 µg, once- indacaterol 300 µg,
indacaterol 600 µg, placebo, and formoterol. Each treatment day will be followed by a
washout-period of 1 week.
Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
Completed
Novartis
Phase 2/Phase 3
2006-11-01
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol
when delivered via an SDDPI in patients with persistent asthma. All patients will receive 1
day of treatment with each of the following: indacaterol 150 µg, indacaterol 300 µg,
indacaterol 600 µg, placebo, and formoterol. Each treatment day will be followed by a
washout-period of 1 week
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
Completed
Merck Sharp & Dohme Corp.
Phase 2
2007-10-01
This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500
μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent
asthma.
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
Completed
Novartis
Phase 2
2007-10-01
This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500
μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent
asthma.
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
Completed
Merck Sharp & Dohme Corp.
Phase 2
2008-01-01
This study will investigate the safety and tolerability of indacaterol maleate/mometasone
furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate
asthma.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
